Shopping Cart
- Remove All
Your shopping cart is currently empty
Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting in a decrease in LDL-C levels. Tafolecimab has potential applications in hypercholesterolemia research [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $332 | 2-4 weeks | |
| 5 mg | $996 | 2-4 weeks | |
| 10 mg | $1,570 | 2-4 weeks |
| Description | Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting in a decrease in LDL-C levels. Tafolecimab has potential applications in hypercholesterolemia research [1]. |
| Cas No. | 2225109-03-3 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.